AA
RETA

ALPS Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

ALPS Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,611
Closed -$546K – 976
2018
Q1 		$546K Buy
26,611
+4,624
+21% +$119K ﹤0.01% 468
2017
Q4 		$623K Buy
21,987
+3,673
+20% +$102K ﹤0.01% 372
2017
Q3 		$570K Buy
18,314
+5,685
+45% +$171K ﹤0.01% 354
2017
Q2 		$400K Buy
+12,629
New +$310K ﹤0.01% 682

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ALPS Advisors's RETA Position: Q2 2018 in Review

ALPS Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2018, closing a stake of 26,611 shares — an estimated $546K sold.

ALPS Advisors first reported a position in RETA in Q2 2017 and held it in 4 quarters. The position peaked at $623K in Q4 2017. 93 funds tracked by Wall St. Rank hold RETA as of Q2 2018.

  • ALPS Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2018 after selling out during the quarter.
  • ALPS Advisors sold 26,611 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2018, an estimated $546K.
  • ALPS Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2017 and held it in 4 quarters.
  • ALPS Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $623K in Q4 2017.
  • 93 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2018.

Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.